PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24019821-4 2013 In this study, we evaluated the effect of bezafibrate as pan PPAR agonist on myocardial capillary density in type I diabetic rats. Bezafibrate 42-53 peroxisome proliferator activated receptor alpha Rattus norvegicus 61-65 26558146-9 2015 Studies in animals have demonstrated the gastric antisecretory activity of PPARalpha agonists like ciprofibrate, bezafibrate and clofibrate. Bezafibrate 113-124 peroxisome proliferator activated receptor alpha Rattus norvegicus 75-84 23428368-3 2013 for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30 mug/100 g BW, oral) and were found to improve in the Bzf co-treated condition. Bezafibrate 85-96 peroxisome proliferator activated receptor alpha Rattus norvegicus 28-76 23428368-3 2013 for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30 mug/100 g BW, oral) and were found to improve in the Bzf co-treated condition. Bezafibrate 159-162 peroxisome proliferator activated receptor alpha Rattus norvegicus 28-76 20851774-0 2010 Activation of PPARalpha by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver. Bezafibrate 27-38 peroxisome proliferator activated receptor alpha Rattus norvegicus 14-23 22841441-3 2012 It was reported recently that bezafibrate (BEZ), an agonist of peroxisome proliferating activator receptor (PPAR), can restore FAO activity in cells from carnitine palmitoyltransferase-2 (CPT2) and very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies as well as clinical symptoms in the adult patients. Bezafibrate 30-41 peroxisome proliferator activated receptor alpha Rattus norvegicus 63-106 22841441-3 2012 It was reported recently that bezafibrate (BEZ), an agonist of peroxisome proliferating activator receptor (PPAR), can restore FAO activity in cells from carnitine palmitoyltransferase-2 (CPT2) and very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies as well as clinical symptoms in the adult patients. Bezafibrate 30-41 peroxisome proliferator activated receptor alpha Rattus norvegicus 108-112 22841441-3 2012 It was reported recently that bezafibrate (BEZ), an agonist of peroxisome proliferating activator receptor (PPAR), can restore FAO activity in cells from carnitine palmitoyltransferase-2 (CPT2) and very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies as well as clinical symptoms in the adult patients. Bezafibrate 43-46 peroxisome proliferator activated receptor alpha Rattus norvegicus 63-106 22841441-3 2012 It was reported recently that bezafibrate (BEZ), an agonist of peroxisome proliferating activator receptor (PPAR), can restore FAO activity in cells from carnitine palmitoyltransferase-2 (CPT2) and very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies as well as clinical symptoms in the adult patients. Bezafibrate 43-46 peroxisome proliferator activated receptor alpha Rattus norvegicus 108-112 22701496-0 2012 Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Bezafibrate 18-29 peroxisome proliferator activated receptor alpha Rattus norvegicus 4-8 21209018-8 2011 CPT-1 inhibitor etomoxir or CPT-1 knockdown augmented PA-induced cell death and reduced T0901317-induced protective effects, whereas the peroxisome proliferator-activated receptor (PPAR)-alpha agonist bezafibrate reduced PA-induced toxicity. Bezafibrate 201-212 peroxisome proliferator activated receptor alpha Rattus norvegicus 137-192 20851774-11 2010 Activation of PPARalpha by bezafibrate negatively affects this process, presumably by decreasing the availability of plasma-borne fatty acids. Bezafibrate 27-38 peroxisome proliferator activated receptor alpha Rattus norvegicus 14-23 20208394-3 2010 In this study, we examined the effects of PPARalpha agonists (ciprofibrate, bezafibrate, fenofibrate and WY14643) on the expression of CAR and its target gene CYP2B1/2 in rat primary hepatocytes. Bezafibrate 76-87 peroxisome proliferator activated receptor alpha Rattus norvegicus 42-51 15840029-2 2005 The regulatory effect of bezafibrate (BZF), a ligand for PPARalpha on glomerulonephritis was investigated using a rat anti-glomerular basement membrane (GBM) glomerulonephritis model. Bezafibrate 25-36 peroxisome proliferator activated receptor alpha Rattus norvegicus 57-66 17521298-2 2007 Bezafibrate, a PPAR-alpha agonist was administered at two different doses of 10 and 100 mg/kg body weight intraperitoneanally. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Rattus norvegicus 15-25 18024222-5 2008 The aim of the present study was to investigate the effect of PPARalpha activation by bezafibrate on the sphingomyelin signaling pathway during the first 24h of liver regeneration after PH in the rat. Bezafibrate 86-97 peroxisome proliferator activated receptor alpha Rattus norvegicus 62-71 18024222-10 2008 Therefore, it is concluded that activation of PPARalpha by bezafibrate decreases the growth-stimulatory activity of the sphingomyelin pathway in regenerating rat liver. Bezafibrate 59-70 peroxisome proliferator activated receptor alpha Rattus norvegicus 46-55 15840029-2 2005 The regulatory effect of bezafibrate (BZF), a ligand for PPARalpha on glomerulonephritis was investigated using a rat anti-glomerular basement membrane (GBM) glomerulonephritis model. Bezafibrate 38-41 peroxisome proliferator activated receptor alpha Rattus norvegicus 57-66 15356383-8 2004 PPAR-alpha mRNA significantly increased in the liver on day 3 of BF administration. Bezafibrate 65-67 peroxisome proliferator activated receptor alpha Rattus norvegicus 0-10 15356383-9 2004 We thus conclude that the PPAR-alpha-mediated effects of BF on the expression of liver UCP2 may be one of the factors that helped to decrease insulin levels. Bezafibrate 57-59 peroxisome proliferator activated receptor alpha Rattus norvegicus 26-36 11527545-3 2001 In islets cultured with 300 microM bezafibrate or WY14643 for 8 h, a low glucose concentration induced insulin release and increased the levels of mRNA for PPAR alpha, acyl CoA oxidase, carnitine palmitoyl transferase-1, pyruvate dehydrogenase E1 alpha or pyruvate carboxylase. Bezafibrate 35-46 peroxisome proliferator activated receptor alpha Rattus norvegicus 156-166 11527545-6 2001 We conclude that bezafibrate enhances insulin release through the activation of PPAR alpha gene expression during a short culture period, whereas it may contribute to beta-cell dysfunction through the mechanism of "excessive stimulation" during longer culture periods. Bezafibrate 17-28 peroxisome proliferator activated receptor alpha Rattus norvegicus 80-90 30905023-2 2019 In this study, 1,3,4 thiadiazole Schiff base derivatives were synthesized as potential peroxisome proliferation-activated receptor-alpha (PPARalpha) agonists and characterized using elemental analysis, FTIR, 1H-NMR, 13C-NMR and mass spectroscopy and then tested for their hypolipidemic activity in Triton WR-1339-induced acute hyperlipidemic rat model in comparison with bezafibrate. Bezafibrate 371-382 peroxisome proliferator activated receptor alpha Rattus norvegicus 138-147 12967931-4 2003 (3) The expressions of the mRNAs for PPARalpha and PPARgamma were significantly decreased in STZ-induced diabetic rats (compared with the controls) and this decrease was restored partially, but not completely, by the chronic administration of bezafibrate. Bezafibrate 243-254 peroxisome proliferator activated receptor alpha Rattus norvegicus 37-46